Private equity firms have moved aggressively into the healthcare industry’s more hidden niches: They are pouring billions into the business of clinical drug trials.
After finding success investing in the more obviously lucrative corners of American medicine like surgery centers and dermatology practices private equity firms have moved aggressively into the industry’s more hidden niches: They are pouring billions into the business of clinical drug trials. To bring a new drug to market, the FDA requires pharmaceutical
After finding success investing in the more obviously lucrative corners of American medicine like surgery centers and dermatology practices private equity firms have moved aggressively into the industry's more hidden niches: They are pouring billions into the business of clinical drug trials.
Apax Makes Investment in Nulo
Funds advised by
Nulo to buy out its existing investor group – which includes
CAVU Venture Partners and
Main Post Partners. The company’s portfolio of products spans both dog and cat foods and formats across kibble, wet food, freeze-dried raw, treats, and toppers.
Michael Landa, CEO at Nulo, said, “We’re excited to partner with the Apax Funds, who have the experience and know-how to help us in our next phase of growth. Since its retail launch in 2011, Nulo has rapidly grown into one of the most authentic and differentiated consumer brands in the premium pet food space. With the support of the Apax Funds, we believe we can achieve our ambitious growth plans, offering our innovative food products to more pet-parents, in more locations around the world.”